Ipsen’s partner, Lexicon, announced FDA Priority Review of new drug application for telotristat etiprate for the treatment of carcinoid syndrome
Associated documents
Download
pdf 60 kB
Lexicon Announces FDA Priority Review of New Drug Application for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
May 31, 2016